This 
B
ronchiolitis is the most common lower respiratory tract infection of young children that causes a majority of hospital admissions and considerable morbidities.
1,2 Although respiratory syncytial virus (RSV) is the most common etiologic agent of bronchiolitis and virtually the only agent that induces epidemics, other respiratory viruses can also induce bronchiolitis as parainfluenza type 1 and 3 virus, rhinoviruses, adenoviruses, coronaviruses, and influenza A virus. 3 Although the pathogenesis of viral-induced airway inflammation and hyperreactivity remains largely unknown, both innate and adaptive immune responses are triggered. 4 T-helper 1 (Th1)-and T-helper 2 (Th2)-type responses have been implicated in infants with RSV bronchiolitis, where different studies showed that the cellular response is mainly neutrophilic with some mast cells and eosinophilic infiltration to the infection site. 5 Studies in vitro 6 and in vivo 7 showed that RSV infection induced expression of the 5-lipoxygenase gene, which plays a central role in the biosynthesis of leukotrienes (LTs), thereby increasing the concentration of cysteinyl LTs (CysLTs; LT C 4 , LTD 4 , and LTE 4 ) in the airways. In addition, clinical studies correlated the severity of RSV disease in infants with the concentration of LTC 4 in their respiratory secretions. 8, 9 These mediators play a central role in the pathophysiology of airway obstruction, contributing to mucosal edema, eosinophilic infiltration, mucus hypersecretion, sensory nerve activation, and contraction and proliferation of the bronchial smooth muscle. 10 Effective evidence-based therapy for bronchiolitis is unknown. Bronchodilators are commonly used in the management of bronchiolitis in North America. Bronchodilators produce small short-term improvements that must be weighed against the costs and adverse effects of these agents. 11 Systemic glucocorticoids have been widely prescribed for use in infants and young children with acute viral bronchiolitis. No benefits were found for infants with acute bronchiolitis treated with systemic glucocorticoids when compared with placebo. 12 Current evidence suggests nebulized 3% saline may significantly reduce the length of hospital stay (LOS) and improve Montelukast, the only LT receptor antagonist studied in young children, has been proven useful in increasing the number of symptom-free days and delaying the recurrence of wheeze in patients with postbronchiolitis wheeze. Additionally, montelukast has been shown to be efficacious as an acute episode modifier in children aged 2-14 years with virus-induced wheezing. 14 Montelukast was shown to modify Th2 cytokine pattern such as interleukin (IL)-4 and IL-13 toward Th1 interferon (IFN) ␥ predominance in children with asthma. 15 Also, montelukast was shown to reduce asthma-like exacerbations when treatment was started 7 days after the first symptoms of bronchiolitis. 16 The goal of the present study was to evaluate the use of montelukast as a line of therapy in acute phase of clinically diagnosed bronchiolitis. Special interest is given to its effect on the duration of hospital stay as well as the cytokine profile of patients on admission and discharge.
PATIENTS AND METHODS
This study was designed as an interventional, randomized, double-blind, placebo-controlled, and efficacy study. It included male and female infants aged 1-24 months of age, clinically diagnosed as viral bronchiolitis with respiratory distress preceded by flu-like symptoms resulting into a sort of obstructive emphysema with wheezes and inconstant fine rales. Patients were recruited randomly from the Allergy, Respiratory and Clinical Immunology Unit, Mansoura University Children's Hospital, Egypt. Exclusion criteria included infants with history of prematurity, previous hospital admissions due to respiratory illnesses, history of previous bronchodilator use before this illness, and treatment with corticosteroids before the current illness, in addition to cases with probable immunodeficiency or underlying cardiopulmonary disease.
Controls were taken from infants coming to the hospital for regular routine checkups or vaccinations.
Written informed consent was obtained from the parents or guardians of all cases and controls before enrollment in the study. The study was approved by the local Institutional Review Board of Mansoura University, Egypt.
Clinical assessment was done for all cases including gender, age, family history of asthma or allergy, previous treatments, concurrent diseases, and medications. Physical examination as well as CSs 17 was recorded for each case at admission and after 12, 24, and 48 hours, and at discharge by the same physician (Table 1) .
Sample Size
Our hospital data for the year 2007 have shown that the mean LOS for cases admitted with bronchiolitis was 3 Ϯ 2 days. Assuming a reduction in LOS by 30% (to 2 days) and study power of 80% to detect a clinical significance (␣-error) of 0.05 between interventional groups, we calculated a sample size (n) of 45 patients for each treatment group.
Randomization and Enrollment
Assignment was conducted by randomly permuted blocks using an online randomizer. 18 According to calculated sample size and estimated case losses of 10% (5 cases in each group) random numbers for 50 cases were generated in each group and were kept in the pharmacy ready for use at any time.
Allocation status was concealed in sealed envelopes in the pharmacy, where the pharmacist was contacted on approval of consent and a randomization number was given. Through the study, the investigators, nursing and medical staff, and parents were unaware of which treatment group infants were assigned to.
Montelukast was given in the form of 4-mg sachets (Singulair; Merck, Whitehouse Station, NJ) and placebo was in the form of identical sachets contained an inactive, identical, flavored, look-alike mannitol granules. The physical difference between granules of montelukast and placebo was undetectable by sight or smell. For permission to copy go to www.copyright.com
Intervention
Intervention was started in the evening of the admission day to be continued each evening until discharge. During the first 24 hours of admission montelukast or placebo were given through an orogastric tube as all infants were kept on i.v. fluid therapy because oral feeding was withhold for reasons of their respiratory distress. After 24 hours, as per improvement of respiratory distress, when infants were allowed to have their regular breast or formula feeding, montelukast or placebo therapy was given by a spoon and feeding was held for 1 hour after, because milk may interfere with medication activity.
Compliance was supervised by a study nurse and patients were observed for 30 minutes after ingestion of granules. If vomiting occurred, one additional dose was given. The staff members were blinded as to which study group the patient belonged to. The decisions to discharge subjects was based on clinical grounds "medically fit for discharge," mainly those who had not received supplemental oxygen for 10 hours, had minimal or no chest recessions, and were feeding adequately, with no need for i.v. fluids.
Outcome Measures
The primary outcome measure was the LOS from admission to discharge (LOS in hours). Secondary outcome measures included CSs and plasma cytokine levels of IL-4 and IFN-␥ on admission and discharge days. Follow-up evaluations including CSs, pulse rate, oxygen saturation, and medical fitness for discharge were done twice per day until discharge.
Blood samples were collected using ethylenediaminetetraacetic acid (EDTA) as an anticoagulant and then centrifuged for 15 minutes at 1000 ϫ g within 30 minutes of collection. Plasma were stored at ՅϪ20°C and were thawed at the end of study for analysis of IL-4 and IFN-␥. IL-4 assessment was done by using Quantikine Human IL-4 Immunoassay (R&D Systems, Inc., Minneapolis, MN) and IFN-␥ was assessed using Quantikine Human IFN-␥ Immunoassay (R&D Systems, Inc.) as recommended by the manufacturer.
Statistical Methods
Data were analyzed on the intention-to-treat principle including all enrolled patients. Each variable was visually scanned for normality of distribution using the Kolmogorov-Smirnov test (cutoff at p ϭ 0.05). Variables showing a distribution significantly different from normal were tested by nonparametric methods. For continuous variables, such as age and laboratory parameters, descriptive statistics were calculated and reported as mean Ϯ SD. Continuous variables were compared for the treatment groups using the t-test for independent samples. Posttreatment values were compared with baseline values within each treatment group using the paired t-test for paired samples. Analysis of data was conducted by using SPSS 16.0 statistical analysis software (SPSS, Inc., Chicago, IL).
RESULTS
During the study period, there were 105 infants clinically admitted with acute viral bronchiolitis, 20 of these cases were excluded because they received corticosteroids and bronchodilators in the past. The remaining 85 cases were enrolled and randomized to either limb of treatment (montelukast group versus placebo group; Fig. 1 ). Forty-seven patients received montelukast while the other 38 patients received placebo. Baseline characteristics are shown at Table 2 . There was no significant difference between the two groups in terms of demographic variables.
CSs were nearly similar at baseline in the montelukast (8.654) and placebo groups (8.68). However, at 24 hours from admission there was a significant decrease in CSs in montelukast group (p ϭ 0.01) compared with the placebo group. Also, there was a trend for the montelukast group for better (lower) CSs when compared with the placebo group through the LOS (Table 3) .
Analyzing LOS of bronchiolitis patients receiving montelukast therapy, we observed that the LOS was significantly lower among the montelukast group patients compared with the placebo group patients (p Ͻ 0.05). This was not detected among patients with a positive family history of allergy or asthma when compared with the rest of patients (p Ͼ 0.05; Table 4 ).
Cytokine Analysis
At admission there was a significant increase in plasma levels of IFN-␥ but not in IL-4 in acute viral bronchiolitis patients compared with healthy controls that probably resonates with Th1 immune response. On admission there was a nonsignificant difference between the studied groups in plasma levels of both IFN-␥ and IL-4. After resolution (on discharge) the montelukast group showed a significant decrease in IFN-␥, with a significant increase in both IL-4 and IL-4/IFN-␥ ratio, this was noted among cases with a positive family history of asthma ( Table 5 ). The montelukast group showed nonsignificant correlation between CSs and IFN-␥ (p ϭ 0.24).
DISCUSSION
Previous clinical investigations implicated CysLTs as a cause of airway inflammation during RSV infection, contributing to wheezing and other clinical manifestations of bronchiolitis. Increased LTC 4 For permission to copy go to www.copyright.com centration correlated with clinical severity, being higher in patients with lower respiratory tract involvement than in children with upper respiratory illness alone. 8, 9 Also, another study in intubated patients with severe RSV bronchiolitis found increased LTE 4 in endotracheal aspirates, which correlated well with urinary LTE 4 levels. 19 Furthermore, Takahashi et al. found a threefold increase in urinary LTE 4 
in children with
RSV infection compared with controls but failed to detect any association with atopic dermatitis or with a family history of allergic diseases. 20 These previous studies revealed increased LT synthesis (in nasal lavage, urine, and endotracheal aspirate) during acute viral bronchiolitis.
In our study, the montelukast group showed a significant decrease in LOS compared with the placebo group. This effect was detected among patients with a positive family history of asthma or allergy at nonsignificant levels, suggesting that these patients may have a different drug response among studied groups. This observed decrease of LOS in the montelukast group could be explained by a higher LT production in infants Ͻ6 months of age 21 and increased CysLTs production during acute viral wheeze in preschool children with high serum IgE.
22
Our results showed significant improvement (lower) of CSs on the early course of the disease that was maintained all through the hospital stay among the montelukast group when compared with placebo. This finding was contrary to the study by Amirave et al. who found no benefit from montelukast therapy because none of the outcome measures (LOS and CSs) were significantly different between the montelukast and placebo groups. 23 Collectively, in the current research, the montelukast group showed a significant improvement in both CSs and LOS compared with the placebo group. This brought attention to once-daily montelukast therapy as 24 Volunteers inoculated with a strain of RSV showed strong IFN-␥ responses to virus in blood mononuclear cells. 25 In addition, stronger Th1-like response in sputum cells (higher IFN-␥/IL-5mRNA ratio) during induced colds was associated with milder cold symptoms and more rapid clearance of the virus. 26 In the present study, a significant increase of IFN-␥ was found in infants with acute viral bronchiolitis compared with healthy controls. This surrogates with Th1 immune response to viral bronchiolitis in which early viral infection in the presence of the F (viral fusion) glycoprotein induces Th1 cells to release the Th1 cytokines IL-2, IL-12, and IFN-␥. 27 From a mechanistic view, a distinction may be made between the effect of montelukast on innate versus adaptive immunity. Ji et al. stated that the postbronchiolitis response to montelukast was found to correct Th2/Th1 imbalance when administered after RSV bronchiolitis.
28 Amirav et al. declared a nonsignificant change in IFN-␥ and IL-4/IFN-␥ ratio in both montelukast and placebo groups. 23 On the other aspect, we found a significant decrease in IFN-␥ at discharge in the montelukast group and not in the placebo group. This establishes the positive effect of montelukast on early innate immunity (during viral shedding phase).
Considering this Th1 immune response that was found in our work during the viral shedding phase of acute bronchiolitis, we also identified a Th2 immune response, as shown by the significant increase of the IL-4/IFN-␥ ratio in patients compared with healthy controls. In addition, our study showed an increase in IL-4 after convalescence in both studied groups. This increase of IL-4 that surrogates with Th2 immune response to viral bronchiolitis can be explained by viral bronchiolitis infection during early infancy, which was found to induce or amplify the persistence of Th2 cytokine immune responses.
29 Also, the increased concentration of cystLTs in airways as a response to viral infection, 7, 28 selectively promotes the generation of Th2 cytokines (IL-4, IL-5, IL-6, and IL-10) and, hence, might enhance allergic responses. 30 -32 In conclusion,
• The treatment effect of montelukast seen in this study seems clinically relevant. LOS was significantly lower in the montelukast group when compared with the placebo group.
• Comparing the CSs for the two treatment arms over the hospital stay, it does appear that montelukast had significant effects on the early course of the disease (lower CSs at 24 hours) that was maintained all through the hospital stay. At discharge IFN-␥ (as a mirror image for viral response) showed a significant decrease in the montelukast group and not in the placebo group. This significant decrease of IFN-␥ was correlated with lower CSs in the montelukast group. Regarding all of the data, montelukast can be 
